Wenlong Bao

Publications (2)2.34 Total impact

• Article: The antiemetic effects of magnetotherapy plus granisetron hydrochloride versus granisetron hydrochloride in patients with chemotherapy

  Yongjun Zhang, Shenglin Ma, Aiqin Zhang, Yan Sun, Wenlong Bao
  [show abstract] [hide abstract]
  ABSTRACT: ObjectiveThe aim of this study was to observe and compare the antiemetic effectiveness and adverse events of magnetotherapy plus 5-hydroxytryptamine (5-HT3) receptor inhibitor granisetron hydrochloride vs granisetron hydrochloride alone in patients with chemotherapy. MethodsSixty-four patients were randomized to receive either granisetron hydrochloride alone (control group: granisetron hydrochloride 3 mg intervenous infusion before chemotherapy, from the 1st day of chemotherapy course until the day after chemotherapy course completed) or magnetotherapy plus granisetron hydrochloride (treatment group: the same granisetron hydrochloride regimen plus rotatory magnetotherapy of 1 every day after chemotherapy for 5 begin with chemotherapy). Baseline characteristics were similar in both groups. The patients’ emesia was evaluated according to WHO’s criteria. The density of 5-HT3 was detected by enzyme-linked immunosorbent assay (ELISA). ResultsIn the treatment of acute vomiting, there was no significant difference between two groups (P > 0.05), but in the treatment of tardive vomiting, the effectiveness in treatment group was better than that in control group (P < 0.05). The density of 5-HT3 in treatment group and control group were (225.32 ± 57.29) ng/mL vs (213.00 ± 53.29) ng/mL before chemotherapy and (273.88 ± 75.42) ng/mL vs (313.17 ± 76.36) ng/mL after chemotherapy (P < 0.01); the rate of adverse events was 36.36% and 48.39% respectively in treatment group and control group (P > 0.05). ConclusionMagnetotherapy plus granisetron hydrochloride provide better effectiveness than granisetron hydrochloride alone, and both therapies have synergistic effect. The adverse events didn’t raised in treatment group. Key wordsmagnetotherapy-5-hydroxytryptamine (5-HT3) receptor inhibitor-chemotherapy-vomiting
  The Chinese-German Journal of Clinical Oncology 04/2012; 9(9):543-546.
• Article: Association between C3orf21, TP63 polymorphisms and environment and NSCLC in never-smoking Chinese population.

  Yongjun Zhang, Cuiping Gu, Hua Shi, Aiqin Zhang, Xiangming Kong, Wenlong Bao, Dehou Deng, Lili Ren, Danlin Gu
  [show abstract] [hide abstract]
  ABSTRACT: Recently, two genome-wide association studies in Asia identified gene polymorphisms known as rs4488809, rs9816619 in TP63 and rs2131877, rs952481 in C3orf21. It has been proposed that these polymorphisms are susceptibility loci for non-small cell lung cancer (NSCLC) development among Japanese and Korean populations. We ask whether susceptibility to NSCLC is limited to the Chinese population or whether the environment also affects genetic polymorphisms. We conducted a matched case-control study to explore this question. Results show that polymorphism of TP63 was not associated with NSCLC development, whereas variant genotypes of C3orf21 were nominally associated with a reduced risk of lung adenocarcinoma (OR=0.619, 95% CI=0.390-0.976). These results strongly suggest that environmental agents interact with human genetic polymorphism independent of ethnic background. In addition, the C3orf21 gene may be a potential susceptibility marker for lung adenocarcinoma independent of ethnic background and environmental agents.
  Gene 04/2012; 497(1):93-7. · 2.34 Impact Factor